Jean-Luc Canon

2.0k total citations
35 papers, 1.1k citations indexed

About

Jean-Luc Canon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jean-Luc Canon has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Jean-Luc Canon's work include Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Jean-Luc Canon is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Jean-Luc Canon collaborates with scholars based in Belgium, France and United States. Jean-Luc Canon's co-authors include Mario Campone, Henri Roché, Anne‐Laure Martin, M. Spielmann, Pierre Kerbrat, Jean-Marc Ferrero, Bernard Asselain, Daniel Serin, A. Vindevoghel and Michel Symann and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Jean-Luc Canon

35 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean-Luc Canon Belgium	16	740	473	216	209	97	35	1.1k
Sonali Jindal United States	21	882 1.2×	323 0.7×	144 0.7×	327 1.6×	127 1.3×	45	1.3k
Qijia Xuan China	18	511 0.7×	241 0.5×	161 0.7×	325 1.6×	68 0.7×	30	922
Chantal Bernard-Marty Belgium	14	845 1.1×	441 0.9×	247 1.1×	280 1.3×	81 0.8×	22	1.2k
C. J. Poole United Kingdom	11	478 0.6×	287 0.6×	170 0.8×	134 0.6×	61 0.6×	21	680
Anne O’Dea United States	14	445 0.6×	233 0.5×	207 1.0×	96 0.5×	106 1.1×	45	716
Lola Anagnostaki Sweden	18	435 0.6×	314 0.7×	104 0.5×	295 1.4×	110 1.1×	38	861
Yoshio Tanji Japan	13	745 1.0×	426 0.9×	131 0.6×	372 1.8×	89 0.9×	24	1.2k
Vincenzo Sforza Italy	18	680 0.9×	194 0.4×	362 1.7×	380 1.8×	84 0.9×	58	1.2k
Konstantinos Venetis Italy	22	746 1.0×	350 0.7×	295 1.4×	316 1.5×	70 0.7×	70	1.2k
Todd Riehl United States	13	431 0.6×	185 0.4×	284 1.3×	288 1.4×	54 0.6×	28	831

Countries citing papers authored by Jean-Luc Canon

Since Specialization

Citations

This map shows the geographic impact of Jean-Luc Canon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Luc Canon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Luc Canon more than expected).

Fields of papers citing papers by Jean-Luc Canon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Luc Canon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Luc Canon. The network helps show where Jean-Luc Canon may publish in the future.

Co-authorship network of co-authors of Jean-Luc Canon

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Luc Canon. A scholar is included among the top collaborators of Jean-Luc Canon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Luc Canon. Jean-Luc Canon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Forget, Frédéric, Serafín Morales, Nuhad K. Ibrahim, et al.. (2024). AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.. Journal of Clinical Oncology. 42(16_suppl). TPS1125–TPS1125. 1 indexed citations

Giacchetti, Sylvie, Enora Laas, Thomas Bachelot, et al.. (2023). Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.. Journal of Clinical Oncology. 41(16_suppl). 546–546. 1 indexed citations

Agostinetto, Elisa, Guilherme Nader Marta, Marianne Paesmans, et al.. (2022). ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast. Future Oncology. 18(22). 2383–2392. 15 indexed citations

Berger, Frédérique, Suzette Delaloge, Anne‐Claire Hardy‐Bessard, et al.. (2022). Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open. 12(3). e055821–e055821. 26 indexed citations

Lonez, Caroline, Eric Van Cutsem, Jean‐Pascal Machiels, et al.. (2019). Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. BioDrugs. 33(5). 515–537. 47 indexed citations

Jézéquel, Pascal, Olivier Kerdraon, Hubert Hondermarck, et al.. (2019). Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. Breast Cancer Research. 21(1). 65–65. 76 indexed citations

Lonez, Caroline, Alain Hendlisz, Philippe Aftimos, et al.. (2018). Celyad's novel CAR T-cell therapy for solid malignancies. Current Research in Translational Medicine. 66(2). 53–56. 19 indexed citations

Carrasco, Javier, Christine Galant, Martine Berlière, et al.. (2017). Analysis of T-cell repertoires in early-stage breast carcinomas to evaluate tumor immunogenicity.. Journal of Clinical Oncology. 35(15_suppl). 11554–11554. 1 indexed citations

Grève, Jacques De, Jan P. van Meerbeeck, Johan Vansteenkiste, et al.. (2016). Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). PLoS ONE. 11(3). e0147599–e0147599. 16 indexed citations

10.

Cutsem, Eric Van, Manuel Hidalgo, I. Bazin, et al.. (2015). Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology. 33(3_suppl). 344–344. 19 indexed citations

11.

Cameron, David, Neil L. Spector, Javier Cortés, et al.. (2014). Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.. Journal of Clinical Oncology. 32(15_suppl). TPS665–TPS665. 1 indexed citations

12.

Toffoli, Sébastien, Isabelle Bar, Fadi Abdel‐Sater, et al.. (2014). Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. Breast Cancer Research. 16(6). 466–466. 30 indexed citations

13.

Roca, Lise, Véronique Dièras, Henri Roché, et al.. (2013). Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial. Breast Cancer Research and Treatment. 139(3). 789–800. 48 indexed citations

14.

Forget, Patrice, Jean‐Pascal Machiels, Pierre G. Coulie, et al.. (2013). Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery. Annals of Surgical Oncology. 20(S3). 650–660. 128 indexed citations

15.

Coudert, Bruno, Bernard Asselain, Mario Campone, et al.. (2012). Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. The Oncologist. 17(7). 900–909. 27 indexed citations

16.

Médioni, Jacques, Joseph Kerger, Lionel D’Hondt, et al.. (2012). Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 70(2). 293–303. 6 indexed citations

17.

Grève, Jacques De, Jan P. van Meerbeeck, Johan Vansteenkiste, et al.. (2011). First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicentre academic phase II study in caucasian patients (pts) (NCT00339586). Journal of Clinical Oncology. 1 indexed citations

18.

Siena, Salvatore, Yves Humblet, Eric Van Cutsem, et al.. (2006). Treatment effect of panitumumab in subsets by epidermal growth factor receptor (EGFR) status from a phase 3 randomized controlled trial. Annals of Oncology. 17. 249–249. 2 indexed citations

19.

Roché, Henri, P. Fumoleau, M. Spielmann, et al.. (2006). Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. Journal of Clinical Oncology. 24(36). 5664–5671. 401 indexed citations

20.

Focan, Christian, M. Beauduin, F. Majois, et al.. (2004). High-Dose Oral Medroxyprogesterone Acetate or Tamoxifen as Adjuvant Hormone Therapy for Node-Negative Early-Stage Breast Cancer: Randomized Trial with 7-Year Update. Clinical Breast Cancer. 5(2). 136–141. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact